index - CRCL-Résistance hormonale, méthylation et cancer du sein

Sébastien Martinez, Stéphanie Sentis, Coralie Poulard, Olivier Trédan, Muriel Le Romancer. Role of PRMT1 and PRMT5 in Breast Cancer. International Journal of Molecular Sciences, 2024, 25, ⟨10.3390/ijms25168854⟩. ⟨hal-04765663⟩
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, et al.. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature Communications, 2024, 15 (1), pp.5931. ⟨10.1038/s41467-024-46999-x⟩. ⟨hal-04765682⟩
Loïc Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, et al.. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST. Acta Oncologica, 2024, 63, pp.411 - 417. ⟨10.2340/1651-226x.2024.32745⟩. ⟨hal-04765764⟩
Gilles Freyer, Anne Floquet, Olivier Trédan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
Aina Bellver-Sanchis, Qizhi Geng, Gemma Navarro, Pedro A Ávila-López, Júlia Companys-Alemany, et al.. G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer’s Disease. Aging and disease, 2024, 15, pp.311-337. ⟨10.14336/ad.2023.0424-2⟩. ⟨hal-04481784⟩
Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, et al.. Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine, 2024, 13 (7), pp.e7115. ⟨10.1002/cam4.7115⟩. ⟨hal-04646005⟩

Derniers manuscrits de l'équipe

Chiffres clés